From January to April 2026, Russians purchased 13.2 million minimum dosage units (MDU) of ectoparasitic veterinary drugs (groups P03 and P53) worth RUB 8.1 billion (at retail prices, including VAT). The physical growth rate compared to January–April 2025 was recorded at +2.6%, the most modest figure over the past four years. For comparison, the growth rate for the full year 2025 was +3.7%, while in 2024 compared to 2023, demand increased by 7.3%. The market is evidently approaching a saturation point, driven both by active import substitution and the activity of a number of foreign manufacturers. The ruble growth rate compared to January–April 2025 was 12.2%, also the lowest value in the past four years; previously, the inflation factor had a strong influence here.

According to the "Retail Audit of Veterinary Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, the ruble share of domestic flea and tick drugs in January–April 2026 amounted to 47.9%, an increase of 4.4% compared to the same period in 2025. However, in the full year 2025, Russian companies' products already accounted for a 52.1% share in the category. In physical terms, domestic manufacturers in January–April 2026 accounted for a 75.5% share, equivalent to 10 million minimum dosage units, although absolute sales decreased by 0.2% compared to the same period in 2025, which also affected the reduction in the overall share of such drugs on the market — over the year, it lost 2.1%, a result of the displacement of cheap products from the market. The category features products from 29 Russian companies, but the main stakeholders are three. The leading one is Ecoprom with an 18.1% ruble share in January–April 2026; the company sells 8 trademarks, the key ones being Inspector and Rolfclub 3D. Second place among domestic companies is held by Vetfarmstandart with the single drug Tixfli, which holds a 15.1% share in the group, and the top three is rounded out by Agrovetzashchita (7.3%), whose main products are represented by the Bars and Okvet lines.

Second place in terms of total market share in the category is held by American manufacturers. In January–April 2026, they accounted for 45.7% of the total ruble volume of the insectoacaricide market, a 3% decrease compared to the same period in 2025. However, compared to the overall results of 2025, there is a 5.6% increase. Interestingly, despite the overall leadership of Russian manufacturers, the flea and tick drug group is led by the American company Zoetis, whose trademark Simparica accounts for 26.3% of the market. MSD also maintains a notable position with a 11.9% share for its drug Bravecto, despite growing pressure from direct analogues.

Among foreign manufacturers, KRKA should also be noted. It is the only Slovenian manufacturer in the category that has managed to radically increase its market share over the past three years. In January–April 2026, the company's share was 3.1%, compared to no more than 1.2% in 2022. Within the group, the manufacturer markets the brands Fiprist and Ataxa.

Fig. Structure of the Russian Retail Market for Ectoparasitic Veterinary Drugs by Country of Origin (including online channel) in Monetary Terms, % RUB

This review analyzes the following groups of veterinary drugs according to the WHO classification: P03 — Ectoparasitic drugs (including scabies mites), insecticides and repellents; and P53 — Ectoparasitic veterinary drugs, insecticides and repellents.